Tumor screening is an important way to detect cancer and precancerous lesions at an early stage. Tumor screening mainly includes three application scenarios: early tumor screening and detection market, MRD (Minimal Residual Disease) micro-residual lesion detection market and cancer treatment and optimized detection market. It is expected that from 2022 to 2026, the total market size will maintain a compound annual growth rate of 12.1%, and by 2026, the size of the tumor screening and detection market will reach US$100 billion.

According to China's "14th Five-Year Plan" goals, by 2030, the average life expectancy of Chinese people will exceed 79 years, and early cancer screening will also be one of the important means to achieve this strategic goal.

The main technical means for tumor screening include fluorescent quantitative PCR, chemiluminescence and lateral flow technology. Jiachun Diagnostics has accumulated many years of practical experience in different detection platforms in this field. The following are some of the related products that our company can develop.

If you need any information, please contact us